



FIMECS Presents at 20th Annual Drug Discovery Summit

Kanagawa, Japan, 29 May 2019 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Yusuke Tominari, Ph.D., Chief Executive Officer and Chief Scientific Officer of FIMECS, will make a presentation at 20th Annual Drug Discovery Summit (11-12 June, 2019 in Berlin, Germany). Title is “Case Study of Targeted Protein Degradation For Immune-Oncology Program, IRAK-M Degradation” and we will present the progress of our IRAK-M degrader program.

For more information:

<https://www.oxfordglobal.co.uk/drugdiscovery-summit1/>

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. <https://www.fimecs.com/eng/>

###

FIMECS, Inc. Media and Investor Contact:

Yusuke Kohno, CFO and VP of Corporate Development

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

TEL: +81-50-5328-9458

E-mail: info@fimecs.com